{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:09:58Z","timestamp":1791655798531,"version":"4.3.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T00:00:00Z","timestamp":1492128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T00:00:00Z","timestamp":1492128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1038\/cgt.2017.9","type":"journal-article","created":{"date-parts":[[2017,4,14]],"date-time":"2017-04-14T10:21:28Z","timestamp":1492165288000},"page":"189-193","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":111,"title":["The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials"],"prefix":"10.1038","volume":"24","author":[{"given":"L","family":"Ansari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Shiehzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Taherzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Nikoofal-Sahlabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A A","family":"Momtazi-borojeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Eslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,14]]},"reference":[{"key":"BFcgt20179_CR1","first-page":"441","volume":"27","author":"B Mlineritsch","year":"2004","unstructured":"Mlineritsch B, Mayer P, Rass C, Reiter E, Russ G, Vesenmayer G et al. Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure. Onkologie 2004; 27: 441\u2013446.","journal-title":"Onkologie"},{"key":"BFcgt20179_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000065716","volume":"63","author":"V Gebbia","year":"2002","unstructured":"Gebbia V, Mauceri G, Fallica G, Borsellino N, Tirrito ML, Testa A et al. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I\u2013II clinical investigation. Oncology 2002; 63: 23\u201330.","journal-title":"Oncology"},{"key":"BFcgt20179_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000215717","volume":"32","author":"B Mlineritsch","year":"2009","unstructured":"Mlineritsch B, Schabel-Moser R, Andel J, Fridrik M, Moik M, Mayer P et al. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer. Onkologie 2009; 32: 18\u201324.","journal-title":"Onkologie"},{"key":"BFcgt20179_CR4","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/annonc\/mdh218","volume":"15","author":"A Alexopoulos","year":"2004","unstructured":"Alexopoulos A, Karamouzis MV, Stavrinides H, Ardavanis A, Kandilis K, Stavrakakis J et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol 2004; 15: 891\u2013895.","journal-title":"Ann Oncol"},{"key":"BFcgt20179_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ctrv.2008.01.008","volume":"34","author":"S Verma","year":"2008","unstructured":"Verma S, Dent S, Chow BJ, Rayson D, Safra T . Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev 2008; 34: 391\u2013406.","journal-title":"Cancer Treat Rev"},{"key":"BFcgt20179_CR6","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.ejca.2005.12.011","volume":"42","author":"RE Coleman","year":"2006","unstructured":"Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P et al. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer 2006; 42: 882\u2013887.","journal-title":"Eur J Cancer"},{"key":"BFcgt20179_CR7","first-page":"2885","volume":"19","author":"R Krishna","year":"1999","unstructured":"Krishna R, Mayer LD . The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR). Anticancer Res 1999; 19: 2885\u20132891.","journal-title":"Anticancer Res"},{"key":"BFcgt20179_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O'Brien","year":"2004","unstructured":"O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440\u2013449.","journal-title":"Ann Oncol"},{"key":"BFcgt20179_CR9","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1016\/j.ejca.2013.04.027","volume":"49","author":"C Falandry","year":"2013","unstructured":"Falandry C, Brain E, Bonnefoy M, Mefti F, Jovenin N, Rigal O et al. Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial. Eur J Cancer 2013; 49: 2806\u20132814.","journal-title":"Eur J Cancer"},{"key":"BFcgt20179_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CAD.0b013e3282f14a00","volume":"19","author":"ME O'Brien","year":"2008","unstructured":"O'Brien ME . Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs 2008; 19: 1\u20137.","journal-title":"Anticancer Drugs"},{"key":"BFcgt20179_CR11","doi-asserted-by":"publisher","first-page":"456409","DOI":"10.1155\/2013\/456409","volume":"2013","author":"J Lao","year":"2013","unstructured":"Lao J, Madani J, Puertolas T, Alvarez M, Hernandez A, Pazo-Cid R et al. Liposomal doxorubicin in the treatment of breast cancer patients: a review. J Drug Deliv 2013; 2013: 456409.","journal-title":"J Drug Deliv"},{"key":"BFcgt20179_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s00280-007-0605-6","volume":"62","author":"R Addeo","year":"2008","unstructured":"Addeo R, Faiola V, Guarrasi R, Montella L, Vincenzi B, Capasso E et al. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women &gt; or =65 years of age. Cancer Chemother Pharmacol 2008; 62: 285\u2013292.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFcgt20179_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s00280-005-0001-z","volume":"57","author":"M Caraglia","year":"2006","unstructured":"Caraglia M, Addeo R, Costanzo R, Montella L, Faiola V, Marra M et al. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother Pharmacol 2006; 57: 34\u201339.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFcgt20179_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00280-001-0405-3","volume":"49","author":"E Rivera","year":"2002","unstructured":"Rivera E, Valero V, Esteva FJ, Syrewicz L, Cristofanilli M, Rahman Z et al. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer Chemother Pharmacol 2002; 49: 299\u2013302.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFcgt20179_CR15","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1200\/JCO.1997.15.10.3185","volume":"15","author":"MR Ranson","year":"1997","unstructured":"Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A . Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997; 15: 3185\u20133191.","journal-title":"J Clin Oncol"},{"key":"BFcgt20179_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000093005","volume":"70","author":"SE Al-Batran","year":"2006","unstructured":"Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N et al. Reduced incidence of severe palmar\u2013plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40\u2009mg\/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 2006; 70: 141\u2013146.","journal-title":"Oncology"},{"key":"BFcgt20179_CR17","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/sj.bjc.6603158","volume":"94","author":"SE Al-Batran","year":"2006","unstructured":"Al-Batran SE, Bischoff J, von Minckwitz G, Atmaca A, Kleeberg U, Meuthen I et al. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer 2006; 94: 1615\u20131620.","journal-title":"Br J Cancer"},{"key":"BFcgt20179_CR18","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","volume":"89","author":"O Lyass","year":"2000","unstructured":"Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000; 89: 1037\u20131047.","journal-title":"Cancer"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cgt20179.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt20179","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/cgt.2017.9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/cgt20179.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T13:10:37Z","timestamp":1647954637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt20179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,14]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["BFcgt20179"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2017.9","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,14]]},"assertion":[{"value":"8 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}